Raymond James analyst Michael Freeman reiterated a Strong Buy rating and $65.00 price target on Avidity Biosciences (NASDAQ: RNA).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE